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Leucine and valine are formed in a common pathway from pyruvate
in which the ®rst intermediate is 2-acetolactate. In some bacteria, this
compound also has a catabolic fate as the starting point for the
butanediol fermentation. The enzyme (EC 4.1.3.18) that forms
2-acetolactate is known as either acetohydroxyacid synthase (AHAS)
or acetolactate synthase (ALS), with the latter name preferred for the
catabolic enzyme. A signi®cant difference between AHAS and ALS
is that the former requires FAD for catalytic activity, although the
reason for this requirement is not well understood. Both enzymes
require the cofactor thiamine diphosphate. Here, the crystallization
and preliminary X-ray diffraction analysis of the Klebsiella
pneumoniae ALS is reported. Data to 2.6 AÊ resolution have been
collected at 100 K using a rotating-anode generator and an R-AXIS
IV++ detector. Crystals have unit-cell parameters a = 137.4, b = 143.9,
c = 134.4 AÊ ,  = 90,  = 108.4,  = 90 and belong to space group C2.
Preliminary analysis indicates that there are four monomers located
in each asymmetric unit.
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1. Introduction
2-Acetolactate is the precursor of the
branched-chain amino acids valine and leucine.
The biosynthetic pathway for these amino
acids is widely distributed in plants, fungi, algae
and bacteria. In some bacteria, 2-acetolactate
also has another entirely different fate in
butanediol fermentation. Decarboxylation of
2-acetolactate yields acetoin, while oxidative
decarboxylation yields diacetyl; the latter can
be reduced to acetoin then further reduced to
butanediol. Both acetoin and diacetyl are
important ¯avour components in fermented
dairy products (Curic et al., 1999) and in beer
(Dulieu et al., 2000).
The formation of 2-acetolactate involves the
decarboxylation of pyruvate followed by
condensation with a second molecule of pyru-
vate. The enzyme that catalyzes this reaction
(EC 4.1.3.18; reviewed by Duggleby & Pang,
2000) is known as either acetohydroxyacid
synthase (AHAS) or acetolactate synthase
(ALS). In common with many other enzymes
that cleave a CÐC bond adjacent to a carbonyl
group, AHAS/ALS uses thiamine diphosphate
(ThDP) as a cofactor. Unexpectedly, the
enzyme from many species (StoÈ rmer &
Umbarger, 1964; Schloss et al., 1985; Chang &
Duggleby, 1997; Pang & Duggleby, 1999) also
requires ¯avin adenine dinucleotide (FAD) as
a cofactor. However, this is not a universal
requirement and StoÈ rmer (1968) showed
clearly that the enzyme from Aerobacter
aerogenes (now Klebsiella aerogenes) is FAD-
independent. It now seems apparent that the
FAD-dependent enzyme produces 2-aceto-
lactate for anabolic branched-chain amino-acid
biosynthesis, while the FAD-independent form
supplies the precursor for catabolic butanediol
formation. Consistent with this distinction is
the observation that the FAD-dependent
enzyme can also combine pyruvate with
2-ketobutyrate to give 2-aceto-2-hydroxy-
butyrate, the precursor of isoleucine, while the
FAD-independent form is speci®c for
2-acetolactate synthesis. A further difference
between the two forms is that the anabolic
enzyme contains both catalytic and regulatory
subunits (Squires et al., 1983; Pang & Duggleby,
1999; Lee & Duggleby, 2001), while the cata-
bolic form lacks a regulatory subunit. The
regulatory subunit confers upon the anabolic
enzyme sensitivity to feedback regulation by
branched-chain amino acids (Vyazmensky et
al., 1996; Pang & Duggleby, 1999; Lee &
Duggleby, 2001). To reinforce the distinction
between the two types of enzyme, it has been
proposed (Gollop et al., 1989) that the name
ALS is reserved for the catabolic FAD-
independent enzyme, while AHAS refers to
the anabolic enzyme that requires FAD.
Notwithstanding the different cofactor
requirements, subunit structure, sensitivity to
inhibition by branched-chain amino acids and
substrate speci®city of ALS and AHAS, the
two proteins are clearly related and show
substantial sequence similarities.
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Recently, we reported the crystallization
(Pang et al., 2001) and structure determina-
tion (Pang et al., 2002) of the catalytic
subunit of Saccharomyces cerevisiae AHAS.
This ®rst experimental AHAS structure
de®nes the position of FAD near the active
site, but offers no obvious clue as to why
there is an absolute requirement for this
cofactor. To further investigate the role of
FAD, we have now crystallized the FAD-
independent ALS from K. pneumoniae and
commenced structure determination.
2. Materials and methods
2.1. Expression, purification and
preparation
The ilvK gene encoding the FAD-
independent ALS from K. pneumoniae was
isolated from the plasmid pTL8 (Peng et al.,
1992). The gene was ampli®ed by PCR and
cloned into the pET30a(+) vector, giving the
expression plasmid pET.ilvk. The recombi-
nant ALS expressed from this plasmid has a
deduced molecular weight of 61.3 kDa.
The protein possesses a native N-terminal
sequence but has seven additional
C-terminal residues: glutamate followed by
a hexahistidine sequence.
The expression plasmid was used to
transform E. coli strain BL21(DE3) cells and
transformants were selected and grown at
310 K in Luria±Bertani medium containing
50 mg mlÿ1 kanamycin. Recombinant ALS
production was induced at 295 K with
0.5 mM IPTG and cells were harvested after
4 h as described previously for yeast AHAS
(Pang & Duggleby, 1999). Cell lysis and
puri®cation of the expressed hexahistidine-
tagged protein by immobilized metal-af®nity
chromatography was as described previously
(Pang & Duggleby, 1999), except that no
FAD was added to the puri®cation buffers.
Eluted fractions containing ALS were
pooled and concentrated by precipitation
with 65% saturated ammonium sulfate. The
protein pellet (10 mg) was resuspended in
2.5 ml storage buffer (50 mM potassium
phosphate pH 7.0 containing 1 mM ThDP,
1 mM MgCl2 and 1 mM DTT) and insoluble
protein was removed by centrifugation. The
clear ALS solution was desalted using a
Pharmacia PD-10 column equilibrated with
storage buffer. The desalted protein solution
was concentrated by ultra®ltration and was
further puri®ed using a Superdex HR10/30
size-exclusion FPLC column. Puri®ed ALS
was eluted using storage buffer. For long-
term storage and crystallization experi-
ments, the protein solution was concentrated
to about 9 mg mlÿ1, divided into small
aliquots and stored at 203 K. The puri®ed
enzyme appears to be homogeneous by
SDS±PAGE and has a speci®c activity of
150 U mgÿ1.
2.2. Crystallization and data collection
Crystallization trials were performed
using the hanging-drop vapour-diffusion
method at 290 K. Prior to each crystal-
lization experiment, DTT was added to the
freshly thawed enzyme aliquot to a ®nal
concentration of 5 mM. The search for
suitable crystallization conditions was
carried out using Hampton Crystal Screens I
and II. Nine of the conditions tested yielded
protein crystals. Preliminary X-ray diffrac-
tion experiments showed that some of the
crystal forms, particularly those grown in the
presence of high concentrations of organic
solvents, diffracted in the range 3±4 AÊ , had a
large unit cell and were unstable. Crystal-
lization using PEG 8000 and ethylene glycol
as the precipitants was selected
for optimization by the grid-
screen approach (Bergfors,
1999). Optimal crystal growth
was obtained by combining 1 ml
of ALS solution with 0.5 or 1 ml
of a reservoir solution consisting
of 0.1 M HEPES pH 7.5±7.7,
6±8%(w/v) PEG 8000 and 6±
9%(v/v) ethylene glycol. Protein
crystals as needles (Fig. 1a) or
plate clusters (Fig. 1b) were
visible after 1 d of incubation but
took one to two weeks to reach
their maximum size. Well formed
plate-like rhombohedral prisms
were chosen for the X-ray
diffraction experiments.
Preliminary X-ray studies with
these crystals at room tempera-
ture using a rotating-anode
generator showed diffraction
to about 2.9 AÊ resolution.
However, the diffraction inten-
sity of the crystals decreased
Figure 1
Crystals of K. pneumoniae ALS. (a) Needles; (b)
plates.
Figure 2
A 0.5 oscillation frame of a cryocooled crystal of K. pneumoniae
ALS. Diffraction data are observed to better than 2.6 AÊ resolution.
Table 1
Data-collection statistics for K. pneumoniae ALS.
Values in parentheses are statistics for the 2.70±2.60 AÊ
resolution shell.
Temperature (K) 100
Resolution range (AÊ ) 100.0±2.60
Total No. of observations [I > (I)] 221772 (17751)
No. of unique re¯ections [I > (I)] 71896 (6680)
Completeness (%) 93.8 (87.3)
Rsym² 0.073 (0.157)
hIi/h(I)i 16.5 (5.3)
² Rsym =
P jI ÿ hIij=PhIi, where I is the intensity of an
individual measurement of each re¯ection and hIi is the mean
intensity of that re¯ection.
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quickly after the initial exposure to X-rays
and a cryocooling strategy was developed
where crystals were transferred to 5 ml of
reservoir solution that had 30%(v/v) PEG
600 added for cryoprotection. After the
transfer, the solution containing the crystals
was set up as a hanging drop in a vapour-
diffusion chamber with 1 ml of the hanging-
drop solution used as the well solution. The
crystals were then allowed to dehydrate in
the sealed chamber for 24 h prior to cryo-
cooling. The combination of dehydration
and cryocooling of these crystals in PEG 600
appears to improve the resolution by up to
0.3 AÊ .
A complete data set from these ALS
crystals was collected using an R-AXIS
IV++ detector and an RU-200 rotating-
anode generator operated at 50 kV and
100 mA (Fig. 2). Data images were recorded
with the detector positioned 220 mm from
the crystal. Each oscillation frame was 0.5
in width and was exposed for 180 s. The
diffraction data were processed to 2.6 AÊ
resolution using DENZO (Otwinowski &
Minor, 1997) and were scaled with
SCALEPACK (Otwinowski & Minor,
1997). Averaging of equivalent intensities
allowed characterization of the Laue
symmetry.
3. Results and discussion
The largest crystals of ALS have dimensions
of 0.1  0.1  0.08 mm, diffract to 2.6 AÊ
resolution (Fig. 2), have unit-cell parameters
a = 137.4, b = 143.9, c = 134.4 AÊ ,  = 90,
 = 108.4,  = 90 and belong to space group
C2. The mosaic spread of these crystals is
0.40 at 100 K. Assuming that there are two
dimers or one tetramer in the asymmetric
unit, the Matthews coef®cient (Matthews,
1968) VM is 2.50 AÊ
3 Daÿ1. Based on a value
of 0.74 cm3 gÿ1 for the partial speci®c
volume of the protein, the calculated solvent
content is 51.7%(v/v). Both the Matthews
coef®cient and solvent content are near the
midpoint of the normal range expected for
protein crystals (Matthews, 1968). An
excellent data set to 2.6 AÊ resolution that
has an overall completeness of 93.8% and an
Rsym of 0.073 (Table 1) has been obtained.
We are now attempting to solve the
structure using molecular-replacement
techniques. Using the catalytic subunit of
yeast AHAS (Pang et al., 2002) as the search
model, we have obtained a solution with an
Rfree value of 0.49 at 2.6 AÊ after rigid-body
re®nement.
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